Trial ID
2204+J+A243:I272
Sponsor ID
M23-362
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
Principal Investigator
Mitul Gandhi, MDLocations
Arlington Office
Fairfax Office
Gainesville Office
Learn More About This Trial
Other Relevant Trials
Trial ID
21552
Sponsor ID
RGX-104-001
“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
Trial ID
VS-6766 +Adagrasib
Sponsor ID
VS-6766-204
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)
